Prolactin-Secreting Tumors & Hypogonadism in 22 Men
NEJM 299:847-852, Carter,J.N.,et al, 1978
Clinical Features of Dopamine Agonist Withdrawal Syndrome in a Movement Disorders Clinic
JNNP 84:130-135, Pondal, M.,et al, 2013
Prolactinomas
NEJM 362:1219-1226, Klibanski,A., 2010
Acromegaly
NEJM 355:2558-2573, Melmed,S., 2006
Cabergoline-Related Severe Restrictive Mitral Regurgitation
NEJM 353:1974-1975, Rosen,C.J., 2005
Heart Valvular Disease in Patients with Parkinson's Disease Treated with High-Dose Pergolide
Neurol 61:859-861, VanCamp,G.,et al, 2003
Chiasmal Herniation as a Complication of Bromocriptine Therapy
J Neuro-Ophthalmol 16:252-257, Taxel,P.,et al, 1996
Cabergoline in Parkinson's Disease:Long-Term Follow-up
Neurol 43:2587-2590, Lera,G.,et al, 1993
Acute Respiratory Failure from Dopamine Agonist Withdrawal
Neurol 42:1843-1844, Riley,D.E.,et al, 1992
Diagnosis and Management of Hormone-Secreting Pituitary Adenomas
NEJM 324:822-831, Klibanski,A.&Zervas,N.T., 1991
Progressive Supranuclear Palsy:Clinical Features & Response to Treatment in 16 Patients
Ann Neurol 13:273-278, Jackson,J.A.,et al, 1983
Successful Use of Bromocriptine in the treatment of a Patient with Chronic Portasystemic Encephalopathy
NEJM 296:793, Morgan,M.Y.,et al, 1977